| |
| |
|
| Insider
Information: |
Gill David N |
| Relationship: |
Director |
| City: |
Knoxville |
| State: |
TN |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
9 |
|
| Direct
Shares |
145,596 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$1,250,821 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
145,596 |
|
|
| Total
Value |
$1,250,821 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
1
|
2
|
|
Stock
price went up :
|
1
|
0
|
| Stock
price went down : |
0
|
2
|
| |
|
|
|
Gain/Loss Ratio : |
1.0
|
-2.0
|
| Percentage
Gain/Loss : |
 31.5%
|
 -62.4%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Nxstage Medical, Inc. |
NXTM |
SVP & CFO |
2006-05-10 |
7,442 |
2006-05-10 |
0 |
Premium* |
|
|
Lemaitre Vascular Inc |
LMAT |
Director |
2007-05-16 |
6,805 |
2006-10-31 |
0 |
Premium* |
|
|
Endochoice Holdings, Inc. |
GI |
President and CFO |
2016-11-22 |
0 |
2016-11-22 |
0 |
Premium* |
|
|
Ocugen Ord Shs |
OCGN |
Director |
2017-08-16 |
14,000 |
2016-12-09 |
0 |
Premium* |
|
|
Melinta Therapeutics, Inc |
MLNT |
Director |
2018-05-25 |
6,000 |
2017-01-03 |
0 |
Premium* |
|
|
Strata Skin Sciences Inc |
SSKN |
|
2019-11-22 |
64,694 |
2018-06-08 |
0 |
Premium* |
|
|
Evolus Inc |
EOLS |
Director |
2024-02-07 |
44,325 |
2018-12-14 |
0 |
Premium* |
|
|
Strongbridge Biopharma Plc |
SBBP |
Director |
2021-10-05 |
0 |
2019-09-03 |
0 |
Premium* |
|
|
Y-Mabs Therapeutics Inc |
YMAB |
Director |
2023-06-08 |
2,330 |
2020-11-03 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| EOLS |
Evolus Inc |
Director |
– • – |
2024-02-07 |
4 |
A |
$0.00 |
$0 |
D/D |
6,464 |
44,325 |
0 |
- |
|
| YMAB |
Y-Mabs Therapeutics Inc |
Director |
– • – |
2023-06-08 |
4 |
A |
$0.00 |
$0 |
D/D |
2,330 |
2,330 |
0 |
- |
|
| EOLS |
Evolus Inc |
Director |
– • – |
2023-01-27 |
4 |
A |
$0.00 |
$0 |
D/D |
8,293 |
37,861 |
0 |
- |
|
| EOLS |
Evolus Inc |
Director |
– • – |
2022-05-16 |
4 |
S |
$13.62 |
$68,080 |
D/D |
(5,000) |
29,568 |
0 |
% |
|
| EOLS |
Evolus Inc |
Director |
– • – |
2022-05-13 |
4 |
S |
$13.10 |
$69,584 |
D/D |
(5,313) |
34,568 |
0 |
% |
|
| EOLS |
Evolus Inc |
Director |
– • – |
2022-01-24 |
4 |
A |
$0.00 |
$0 |
D/D |
15,568 |
39,881 |
0 |
- |
|
| SBBP |
Strongbridge Biopharma Pl... |
Director |
– • – |
2021-10-05 |
4 |
D |
$0.00 |
$0 |
D/D |
(78,058) |
0 |
0 |
- |
|
| SBBP |
Strongbridge Biopharma Pl... |
Director |
– • – |
2021-10-01 |
4 |
D |
$2.06 |
$36,592 |
D/D |
(17,763) |
78,058 |
0 |
- |
|
| SBBP |
Strongbridge Biopharma Pl... |
Director |
– • – |
2021-05-18 |
4 |
A |
$0.00 |
$0 |
D/D |
40,000 |
95,821 |
0 |
- |
|
| SBBP |
Strongbridge Biopharma Pl... |
Director |
– • – |
2021-05-14 |
4 |
D |
$2.35 |
$44,826 |
D/D |
(19,075) |
55,821 |
0 |
- |
|
| EOLS |
Evolus Inc |
Director |
– • – |
2021-02-05 |
4 |
A |
$0.00 |
$0 |
D/D |
19,313 |
24,313 |
0 |
- |
|
| YMAB |
Y-Mabs Therapeutics Inc |
Director |
– • – |
2021-01-19 |
4 |
AS |
$46.52 |
$93,045 |
D/D |
(2,000) |
0 |
0 |
% |
|
| YMAB |
Y-Mabs Therapeutics Inc |
Director |
– • – |
2021-01-19 |
4 |
OE |
$11.16 |
$22,320 |
D/D |
2,000 |
2,000 |
0 |
- |
|
| YMAB |
Y-Mabs Therapeutics Inc |
Director |
– • – |
2020-11-18 |
4 |
OE |
$11.16 |
$22,320 |
D/D |
2,000 |
2,000 |
0 |
- |
|
| YMAB |
Y-Mabs Therapeutics Inc |
Director |
– • – |
2020-11-18 |
4 |
AS |
$45.77 |
$91,530 |
D/D |
(2,000) |
0 |
0 |
% |
|
| YMAB |
Y-Mabs Therapeutics Inc |
Director |
– • – |
2020-11-03 |
4 |
AS |
$45.00 |
$180,000 |
D/D |
(4,000) |
0 |
0 |
% |
|
| YMAB |
Y-Mabs Therapeutics Inc |
Director |
– • – |
2020-11-03 |
4 |
OE |
$11.16 |
$44,640 |
D/D |
4,000 |
4,000 |
0 |
- |
|
| SBBP |
Strongbridge Biopharma Pl... |
Director |
– • – |
2020-09-24 |
4 |
B |
$2.13 |
$17,040 |
D/D |
8,000 |
74,896 |
2.39 |
% |
|
| SBBP |
Strongbridge Biopharma Pl... |
Director |
– • – |
2020-09-03 |
4 |
D |
$3.61 |
$83,405 |
D/D |
(23,104) |
66,896 |
0 |
- |
|
| SBBP |
Strongbridge Biopharma Pl... |
Director |
– • – |
2020-05-14 |
4 |
A |
$0.00 |
$0 |
D/D |
40,000 |
90,000 |
0 |
- |
|
| SSKN |
Strata Skin Sciences Inc |
|
• • – |
2019-11-22 |
4 |
A |
$0.00 |
$0 |
D/D |
18,293 |
64,694 |
0 |
- |
|
| SBBP |
Strongbridge Biopharma Pl... |
Director |
– • – |
2019-09-03 |
4 |
A |
$0.00 |
$0 |
D/D |
50,000 |
50,000 |
0 |
- |
|
| EOLS |
Evolus Inc |
Director |
– • – |
2019-06-13 |
4 |
B |
$13.65 |
$27,300 |
D/D |
2,000 |
5,000 |
2.39 |
- |
|
| EOLS |
Evolus Inc |
Director |
– • – |
2018-12-14 |
4 |
B |
$12.77 |
$38,300 |
D/D |
3,000 |
3,000 |
2.39 |
- |
|
| SSKN |
Strata Skin Sciences Inc |
Director |
– • – |
2018-06-08 |
4/A |
A |
$0.00 |
$0 |
D/D |
31,401 |
46,401 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
